STOCK TITAN

United Therapeutics Corporation To Present At The Credit Suisse 29th Annual Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

United Therapeutics Corporation (Nasdaq: UTHR) announced that President and COO Michael Benkowitz will present at the Credit Suisse 29th Annual Virtual Healthcare Conference. The presentation is scheduled for November 9, 2020, from 2:45 to 3:25 p.m. EST, and will be accessible via a live webcast on the company's website. An archived version will be available 24 hours post-event for 90 days. United Therapeutics focuses on innovation and sustainability in biotechnology, particularly through its subsidiary Lung Biotechnology PBC, which addresses the shortage of transplantable organs.

Positive
  • None.
Negative
  • None.

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 2, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Credit Suisse 29th Annual Virtual Healthcare Conference.

The presentation will take place on Monday, November 9, 2020, from 2:45 to 3:25 p.m., Eastern Standard Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the presentation will be available approximately 24 hours after the session ends and can be accessed at the same location for 90 days.

About United Therapeutics

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment, and society – will sustain our success in the long term.

Through our wholly owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements relating to our ability to create value and sustain our success in the long-term, as well as our efforts to develop technologies that either delay the need for transplantable organs or expand the supply of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of November 2, 2020 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.

*          *          *

For Further Information Contact:
Dewey Steadman at (202) 919-4097
Email: ir@unither.com   

Cision View original content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-to-present-at-the-credit-suisse-29th-annual-virtual-healthcare-conference-301164190.html

SOURCE United Therapeutics Corporation

FAQ

What time is United Therapeutics' presentation at the Credit Suisse 29th Annual Virtual Healthcare Conference?

United Therapeutics' presentation is scheduled for November 9, 2020, from 2:45 to 3:25 p.m. EST.

Where can I watch the United Therapeutics presentation during the Credit Suisse conference?

You can watch the United Therapeutics presentation via a live webcast on their official website.

What is the focus of United Therapeutics as a biotechnology company?

United Therapeutics focuses on innovative solutions in biotechnology, particularly in addressing the shortage of transplantable organs.

Who is presenting for United Therapeutics at the Credit Suisse conference?

Michael Benkowitz, the President and COO, will present for United Therapeutics at the conference.

How long will the archived presentation of United Therapeutics be available?

The archived presentation will be available for 90 days after the live event.

What is the stock symbol for United Therapeutics?

The stock symbol for United Therapeutics is UTHR.

United Therapeutics Corp

NASDAQ:UTHR

UTHR Rankings

UTHR Latest News

UTHR Stock Data

16.28B
44.65M
1.85%
105.2%
4.92%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SILVER SPRING